27EC Den, Robert B. - Thomas Jefferson University - Thomas Jefferson University

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Novel targeted siRNA-loaded hybrid nanoparticles: Preparation, characterization and in vitro evaluation
  2. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis
  3. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  4. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  5. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes
  6. Uncertainties encountered in implementation of adaptive planning with in vivo dosimeters
  7. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data
  8. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes
  9. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
  10. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  11. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  12. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  13. Practical guide to the use of radium 223 dichloride
  14. High dose rate brachytherapy boost for prostate cancer: A systematic review
  15. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  16. Introduction
  17. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  18. Effect of docetaxel on safety and efficacy of radium-223
  19. RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1
  20. Large prostate gland size is not 0166 a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma